2024 was also the year where Merck looked at inorganic growth to expand its pharmaceuticals and animal health business ... The U.S. FDA has set a deadline of June 10 to make a decision on approval ...

Merck & Co Inc (NYSE:MRK) is making significant progress in its pipeline, with 20 potential new growth drivers, many with blockbuster potential. The Animal Health business delivered strong ...

VBMA students are invited to compete in a scholarship program aiming to prepare the next generation of veterinarians for entrepreneurship ...

In Canada, Merck markets a broad range of vaccines, pharmaceutical and animal health products and is one of the top R&D investors in Canada, with investments totaling more than $90 million in 2022 and ...

the successful launch of WINREVAIR and strong performance of our Animal Health business," said Robert Davis, chairman and chief executive officer, Merck. Also Read: RJK Jr.'s Involvement In Merck ...

the successful launch of WINREVAIR and strong performance of our Animal Health business," said Robert M. Davis, chairman and CEO of Merck. Merck also said it has temporarily paused shipments of ...

Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street's estimates, boosted in part by the performance of top asset Keytruda. The drug company logged net income of $3.74 ...

Merck said it expected sales of $64.1 billion to $65.5 billion in 2025 and adjusted earnings of $8.88 to $9.03 a share. Both forecasts came in below the average analyst expectation for revenue of ...

Merck (MRK) stock was mangled today after the ... successful launch of WINREVAIR and strong performance of our Animal Health business.” Is MRK Stock a Buy, Sell, or Hold? Turning to Wall Street, ...

Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in ...